We show that the previously described alloantisera Ond and Mart, which recognize the alloantigens Ond" and Mart", react with polymorphic variants of aL and aM subunits of the p2 integrin family (CDlla and CDllb molecules). This was shown by testing the alloantisera in a monoclonal antibodyspecific immobilization of leukocyte antigens, immunoprecipitation, and immunofluorescence assay against cells from normal donors and from patients with leukocyte adhesion deficiency (p2 integrin deficient). To elucidate the molecular basis of the Ond" and Mart" alloantigens, RNA was isolated from mononuclear leukocytes derived from individuals of known serologic phenotype. Reverse transcriptase-polymerase chain reaction (RT-PCR) was performed to amplify the entire coding region of the aL and aM mRNAs. The Ond" H EMATOPOIETIC CELLS express various adhesion molecules, many of which are structurally related and belong to a supergene family, the integrins. Within this superfamily, three families can be distinguished: the Leu-CAM, the VLA, and the cytoadhesin family. The Leu-CAMfamily comprises molecules involved in virtually all cellcell interactions of the immune system.'. antigen was found to be due to a G2466C substitution in the DNA coding for the aL subunit, which predicts an Arg766Thr amino-acid polymorphism. The Mart" antigen was also found to be due to a single nucleotide substitution (G302A) in the DNA coding for the aM subunit, which predicts an Arg6lHis amino acid polymorphism. Using allele-specific restriction enzyme analysis, the association between point mutations and phenotypes was confirmed. The localization of these alloantigens on integrin molecules further illustrates the polymorphic nature of this class of proteins. Whether the polymorphisms influence the adhesive capacity of the leukocyte integrins remains to be investigated.
antigen was found to be due to a G2466C substitution in the DNA coding for the aL subunit, which predicts an Arg766Thr amino-acid polymorphism. The Mart" antigen was also found to be due to a single nucleotide substitution (G302A) in the DNA coding for the aM subunit, which predicts an Arg6lHis amino acid polymorphism. Using allele-specific restriction enzyme analysis, the association between point mutations and phenotypes was confirmed. The localization of these alloantigens on integrin molecules further illustrates the polymorphic nature of this class of proteins. Whether the polymorphisms influence the adhesive capacity of the leukocyte integrins remains to be investigated. 
MATERIALS AND METHODS

Sera
Serum Ond was obtained from a male patient suffering from aplastic anemia and has been described previously." The patient had been transfused with packed red blood cells and platelet concentrates from more than 700 random donors. Despite these transfusions, he never produced antibodies against HLA or platelet-specific antigen~."-~' Moreover, it was shown that he had a markedly prolonged survival of a skin graft from an HLA nonidentical donor (35 days) and from his HLA-compatible brother (70 days)." In the immunofluorescence test, his serum was found to strongly react with lymphocytes. monocytes, and granulocytes. It did not react with the lymphocytes from 4 of 49 donors." The serum also contained anti-NA2 alloantibodies. The inheritance of the target antigen of serum Ond was studied in the family of one of the workers in the lab.
Serum Mart was obtained from a multiparous woman who had no history of giving birth to babies with clinically apparent neonatal alloimmune neutropenia." This serum was reactive in the immunofluorescence test with granulocytes, monocytes, and a subset of lymphocytes.
Serum E27 was kindly provided by Dr K.D. Pischel (University of California, San Diego, CA). Serum CLB120 is a pool of human sera containing a mixture of antibodies against different HLA-anti- 
Monoclonal Antibodies (MoAbs)
The following MoAbs were used: CLB-CD7 (CD7), W6/32 (directed against HLA class-I antigens), CLBLFAI/I (CD18), CLBLFAIR (CDlla), Bear-l (CDllb), and HCUl (CD1 IC). Bear-1 was kindly provided by Dr C. Figdor (Netherlands Cancer Institute, Amsterdam, The Netherlands).'" HClll was a gift of Dr E. SanchezMadrid (Madrid, Spain)." The other antibodies were produced in our own laboratory and were clustered during the Third International Workshop on Leukocyte Differentiation Antigens."
p2 Integrin-Deficient Patients
Two unrelated patients with congenital leukocyte adhesion deficiency (LAD) donated cells for our study. The cells of patient BH express a low but detectable amount (-10%) amount of LFA antigens.'' Patient VI is a newly diagnosed pz integrin-deficient girl, who died from sepsis shortly after birth. No p2 integrin antigens were detectable on her cells.'4 Immunofluorescence tests were performed according to standard methods with PFA-fixed cells.2s
Cells
Granulocytes and mononuclear cells were isolated from heparinized blood by Ficoll-Isopaque density centrifugation (d = 1.077 g/ mL). Lymphocytes and monocytes were further purified by elutriation. Morphologic examination showed greater than 90% purity.
MoAb Immobilization of Leukocyte Antigens (MAILA)
MAILA assay was performed according to Kiefel , precoated with goat-antimouse-Ig (7.5 pg/mL GAM; Jackson, Westgrove, PA) in 0.1 moliL NaHCOlNa2COl pH 9.6 overnight at 4°C. The plate was incubated for 60 minutes at 37"C, followed by 30 minutes at 4°C. After extensive washing at 4"C, the wells were incubated with 100 p L of alkaline phophatase-conjugated rabbit-antihuman-IgG (Jackson) diluted 1:500 in washing buffer for 2 hours at P C , followed by another washing cycle. Finally, the bound conjugate was visualized by adding Sigma 104 R Alkaline Phosphatase substrate (Sigma Chemical CO, St Louis, MO) dissolved in diethanolamine buffer, pH 10. To inhibit endogenous alkaline phophatase activity, levamisole was added to the substrate buffer. The absorbance was measured on a titertec reader. From the precleared lysate, the antibody-antigen complexes were precipitated with polyclonal goat-antimouse-Ig or monoclonal antihuman-IgG covalently coupled to Sepharose 4B-beads by end-overend incubation for 3 hours at 4°C. In sequential immunoprecipiation, the supernatant was incubated with S p L of ascitic fluid 1:10 or 25 p L of human serum, again precipitated with anti-Ig coupled to Sepharose beads. This procedure was repeated 3 times. Finally, the supernatant was precleared with human serum and incubated with MoAbs and vice versa. The isolated antigens were analyzed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), followed by autoradiography.
Immunoprecipiation
Isolation of RNA and cDNA Synthesis
Total cellular RNA from mononuclear leukocytes was prepared by extraction with guanidine thiocyanate and density gradient centrifugation in cesium chloride. cDNA first-strand synthesis was per- 
PCR Amplification of cDNA and Sequence Analysis
Suitable oligonucleotide primers were used to amplify the entire coding region of the aJaM cDNAs. The PCR was performed on 1 pg of cDNA, 100 pmol of each primer, 10 nmol of each dNTP, and 2 U of Taq DNA polymerase (Promega Corp, Madison. WI) diluted in a buffer recommended by the manufacturer in a total volume of 50 pL in a DNA thermal cycler (Model 480; Perkin Elmer-Cetus, Norwalk, CT). An initial denaturation cycle at 95°C for 5 minutes was followed by 35 cycles with denaturation at 95°C for 1 minute, annealing at 55°C for 1.5 minutes, and extension at 72°C for 2.5 minutes. The nucleotide sequence of the overlapping PCR products was determined directly with the cycle sequencing kit with '*Plabeled (Amersham, UK) primers, following the instructions of the manufacturer (GIBCO-BRL).
PCR-Allele-Specific Restriction Enzyme Analysis (PCR-ASRA)
Bsp12861 ASRA to distinguish Ond" from On#-.
A 709-bp segment of the a,. cDNA containing the dimorphism was amplified with oligonucleotide primers L5(2283-2303) 5'tagaartcAmCT-CTCTTTGGGAGGAGG3' and L5A(2996-2977) S'ataagcrTGGG-TATG-TTGTGGTCGTGG3' (extended with EcoRI and Hind111 restriction sites, respectively). Ten microliters of the PCR product was digested with the restriction endonuclease Bspl286I (New England Biolabs, Beverly, MA) and subsequently size-separated on a 2%
For personal use only. on October 27, 2017. by guest www.bloodjournal.org From Absorbance values obtained in the MAILA assay using lymphocytes, monocytes, and granulocytes. The three cell types were incubated simultaneously with the sera under investigation (AB, Ond, or Mart) and the MoAbs CLBLFAI/l(CD18), CLBLFA1/2 (CDlla), Bear-l (CDllb), or HCI/l(CDl IC). The indicated values represent the mean. The number of experiments performed for each combination is given between parentheses. Statistical significance (compared with AB control) was calculated by using the Student's t-test.
Abbreviation: NT, not tested.
agarose gel, stained with ethidium bromide, and visualized with UV light. Aci I ASRA to distinguish Mart"+ from Mart"-. The oligonucleotide primers M36-56 5'TGG7TCACCTCCITCCAGGTT3' and M720-700 5'CTTCACCAGTGATCTTGGGTT3' were used to generate a PCR product of 685 bp from cDNA. An aliquot (10 pL) of the PCR product was subjected to Aci I digestion according to the instructions of the manufacturer (New England Biolabs). The resulting fragments were electrophoresed and visualized on a 2% agarose gel with ethidium bromide and UV light.
RESULTS
GP Recognized by Ond Antibodies
In the immunofluoresecnce test, it was shown that binding of the antibodies present in serum Ond did not interfere with the binding of CD11 or CD18 MoAbs (data not shown). Therefore, it was possible to test this serum in the MAILA. In this assay, a positive signal is only obtained when a human serum contains antibodies against the same GP as the MoAb. The specificity of the assay was shown using a serum with known specificity for HLA class I antigens. This serum (CLB120) produced a much higher signal (mean absorbance value 2.163 2 0.07 1 [ -t SD, n = 51) than an AB serum (0.096 It 0.045) when tested against an MoAb (W6.32) specific for HLA class I molecules. As expected, no positive results were obtained when the two sera under investigation tested against an irrelevant control MoAb (0.204 2 0.07 1 and 0.196 It 0.103, respectively). As shown in Table 1 , Ond serum contained antibodies reactive with the same GP complex (present on monocytes, granulocytes, and lymphocytes) as that recognized by the CD1 l a and CD1 8 MoAbs, ie, the LFA-1 complex. Ond serum did not react with the CD1 l b and CDllc MoAbs. The results obtained with the MAILA strongly suggested that the Ond serum was reactive with the To confirm this finding, sequential immunoprecipitation experiments with Ond serum were performed. As shown in Fig I , GPs of the same molecular weight (MW) were immunoprecipitated from surface-labeled lymphocytes with LFA-l GP.
Ond serum as with anti-LFA-l (CD1 la), ie, 180 kD and 95 kD. After the lymphocyte lysate was precleared with the anti-LFA-l MoAb (CLBLFA1/2), no antigens were precipitated by Ond serum, but cell lysate precleared with an MoAb against a non-LFA antigen (CLB-CD7) still contained the 180-kD and 95-kD proteins recognized by Ond serum. Similarly, lymphocyte lysate precleared with serum Ond no longer contained LFA-1 complex antigens, which could be immunoprecipitated with the MoAbs (Fig 1) . Ond serum reacted in the immunofluorescence assay with lymphocytes and granulocytes obtained from two unrelated LAD patients. However, when these cells were radiolabeled, Ond serum did not precipitate the characteristic bands of 180 and 95 kD, as seen with normal donor cells. These results indicated that Ond serum contained other antibodies in addition to the Ond" antibodies. Indeed, we have previously shown that anti-NA2 antibodies were also present in this serum.*' Pischel et a13 previously described a serum that immunoprecipitated LFA-1 from lymphocytes of 95% of individuals tested. This serum, E27, did not precipitate LFA-1 from a lysate of lymphocytes obtained from the person who donated Ond serum (data not shown), and Ond serum did not immunoprecipitate any GPs from a lysate of the lymphocytes obtained from patient E27 (K, Pischel, personal communication, 1989 ).
Molecular Basis of Ond
Because the results of immunochemical and serological tests with Ond serum indicated that the epitope was located on GP aL, we examined the nucleotide sequence of the aL cDNA derived from lymphocyte RNA obtained from patient Ond. Six overlapping fragments that spanned the entire length of a,. cDNA were amplified by PCR. The nucleotide sequence of the PCR fragments was determined and compared with the previously published sequence of aL cDNA. Three differences were observed: (1) a C to T change at position 1882, predicting no amino acid change (Leuci ne571); (2) an inversion of nucleotides T2072 and A2073, predicting a tyrosine (TAC) to isoleucine (ATC) change at For personal use only. on October 27, 2017. by guest www.bloodjournal.org From position 635; and (3) a G to C substitution at position 2466, predicting an arginine to threonine transformation at position 766 of the mature GP (Fig 2) . These findings prompted us to determine the aL cDNA sequences of five other people whose leukocytes had been Ond-phenotyped (2 On#-and 3 On#+). The C1882T (Leu571) and Tyr(TA C)635Ile(ATC) changes were observed in all donors studied, whereas the G2466C (Arg766Thr) substitution was present in the aL cDNA of 0nd"-donors only.
The G2466C mutation abolishes a target site for the restriction endonuclease Bsp12861, which cleaves at 5'-GAG-CCC'-3 (Ond"') but not at 5"CAGCCC-3' (On#-) sequences ( Fig 3A) . As can be seen from Fig 3B, Ond"' can be clearly distinguised from 0nd'-by cDNA typing with Bspl286I. Moreover, it was possible to identify individuals heterozygous for the Ond" antigen (Fig 3B, lane 3) . Because the genomic structure of LFA-I is not yet known, we were not able to generate a PCR-ASRA using genomic DNA.
Ond Phenotype
We next studied the association of the G2466C (Arg766Thr) polymorphism with the serologically determined Ond phenotypes in a family (phenotyped by MAILA; Fig 4) . Bsp1286I ASRA was performed with PCR products derived from lymphocyte RNA from the members of one family. Full concordance between serology and PCR-ASRA was obtained (data not shown). Moreover, three members of this family appeared to be heterozygous for the G2466C (Arg766Thr) dimorphism. The family of propositus Ond was not studied because they were not available for study.
GPs Recognized by Mart Serum
In the immunofluorescence assay, the binding of the alloantibodies in Mart serum was not blocked by either CD1 1 or CD 18 MoAbs, which made it possible to test this serum in the MAILA assay. As shown in Table 1 , Mart serum reacted in the MAILA assay with a complex recognized by CDllb and CD18 antibodies, ie, the C3bi-receptor (CR3). Immunoprecipitation studies were performed to verify this finding. In initial experiments, no positive results were obtained. Because of the positive results with Mart serum in the MAILA assay, we modified our procedure and performed immunoprecipitation under experimental conditions similar 3) . This result was not due to the cross-reaction of the antihuman-Ig Sepharose beads with murine Ig, because no proteins were immunoprecipitated when the MoAb specific for CR3 was incubated in combination with human AB serum (Fig 5 , lane 4) . Further evidence of the specificity of (> OndatOnda-0 OndatOndat (A) A 709-bp fragment of the LFA-l cDNA was PCR amplified and treated with the restriction endonuclease Bsp72861. In case of Ond" positivity, three fragments of 297 bp, 217 bp, and 195 bp were generated. In the 0nd"-allele, one of the target sites for Bsp12861 was lost and only two fragments of 412 bp and 297 bp were generated. Note that the 297-bp fragment was produced regardless of the Ond genotype. the Mart serum for integrin antigens was provided by the finding that, when Mart serum was tested in the immunofluorescence assay against lymphocytes and granulocytes from the two unrelated LAD patients, no reactions occurred.
Molecular Basis of Murt
To identify the molecular basis of the Mart" antigen. five overlapping segments of the aM cDNA derived from the Mart-donor were amplified by PCR with suitable oligonucleotide primers. Comparison of the nucleotide sequence of the PCR products with the published sequences of aM showed a G to A change at position 302, predicting an arginine to histidine substitution at position 61 of the mature GP (Fig 6) . The two previously described polymorphisms of CD1 I b/aM cDNA, ie, the absence of glutamine at position 478 and a C2969T transition (predicting a Pro950Leu substitution), were not detected in the cDNA of the Mart" donor.""" M a r f Tvping by Aci I ASRA We took advantage of the loss of a target site for the restriction endonuclease Aci I (5'-CCGC-3') by the G302A substitution to type for the Mart" antigen. As can be seen in Fig 7A, a 685 -bp segment in the aminoterminus of the aM cDNA was amplified and subsequently digested with Aci I. In the Mart'+ allele, the PCR product (685 bp) was cleaved into three fragments of 272 bp, 266 bp, and 147 bp, but in the Mart"-allele, due to the absence of one of the Aci I target sites in the 685-bp PCR product, only two fragments of 538 bp and 147 bp were generated. In Fig 7B. the ASRA results obtained with PCR products derived from a Mart"', a Mart-, and an apparently heterozygous donor are shown. The Mart"' members of the Mart family appeared to be Our first indication of the GP specificity of the antisera was obtained from MAILA experiments. O n 8 and Mart" antigens were immobilized by CD18 MoAbs, indicating that the alloantibodies reacted with GPs of the pz family. The finding that On# antigen was immobilized only by anti-a,, and Mart" only by anti-aM antibodies strongly suggested that the sera were reactive with epitopes on the two different crchains, a,. and aM. respectively. The sera were not reactive in the immunoblot technique (data not shown).
Further evidence for the specificity of the sera was obtained by immunoprecipitation. Ond serum immunoprecipitated a 180/95-kD complex, corresponding to the MW of a tity of this complex was finally proven by sequential immunoprecipiation with anti-LFA-I antibodies. Immunoprecipitation studies also showed that the antigen recognized by serum E27, described by Pischel et al' is identical to the O n 8 antigen. Mart serum immunoprecipitated the C3bi receptor (CR3). The latter serum did not react with the cells from heterozygous for the G302A mutation (Fig 8) . Full concordance was obtained between serotyping and genotyping for the Mart" antigen (data not shown).
DISCUSSION
At present, most of the polymorphic antigen systems identified on platelets have been biochemically localized. It is remarkable that at least 8 of these systems are localized on molecules belonging to the integrin supergene family; HPA-I , -3. -4, -6, and -9 and the private platelet antigens Gro" and Va" are present on cytoadhesins'.?" and HPA-5 on VLA-2.2'.24 Although numerous leukocyte antigens have been identified and characterized with murine MoAbs, most non-HLA leukocyte antigen systems defined by human alloantibodies have not yet been biochemically characterized. We have shown that the NA system is located on the Fcy receptor 111 (CD16 antigen).'" Stroncek et al' l and Goldschmeding et alJ2 identified the NB1 antigen on a 58-to 64-kD GP located on the neutrophil plasma membrane and in secondary granules. In the present study, we show that the previously described polymorphic leukocyte antigens O n 8 and Mart" are located on the a,. subunit of the LFA-I complex and the aM subunit of the C3bi receptor, respectively. 
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7.sa sequence analysis. Both alloantigens were found to be associated with single nucleotide substitutions resulting in amino-acid dimorphisms of the corresponding cr chains of the p2 integrin family. Results from DNA typings of phenotyped individuals and family studies suggest that the aminoacid dimorphisms control the expression of the Ond and Mart epitopes on the crL and cyM molecule, respectively. However, this should be definitely proven by the construction and analysis of the reactivity of allele-specific forms of the cr chains with the Ond and Mart alloantisera in expression systems. It is not yet possible to develop a typing technique at the genomic DNA level, because the genomic organization of the crL and crM chains is not yet known. However, based on our findings, such genotyping strategies can be easily designed as soon as the genomic structures have become available.
Thus, similar to that of platelet alloantigens, the molecular basis of the leukocyte alloantigens Ond" and Mart" has been found to be due to single nucleotide substitutions, leading to amino-acid dimorphisms. The localization of two more alloantigen systems on integrin molecules further illustrates the polymorphic nature of this class of proteins. Binding of antibodies to these alloantigens may affect adhesion via such receptors. Antibodies against HPA-la (Zwa) have been shown to inhibit fibrinogen binding to activated platelets.43
The survival of skin grafts on patient Ond was remarkably prolonged. This was possibly due to the alloantibodies against LFA-l present in his serum, which may have blocked leukocyte-leukocyte interactions in the grafts. Thus far, in vitro functional studies with Ond serum have not shown any In conclusion, we located the leukocyte antigens On@ on the cyL chain of the LFA-I complex and Mart" on the aM chain of the C3bi receptor and established the molecular genetic basis for both leukocyte antigens. This shows that antigenic polymorphisms also occur in the p2 integrin family of integrins.
